Trump announces trade deal with EU following months of negotiations
Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), recently sold 53,000 shares of the company’s common stock. The transaction, which took place on March 12, 2025, was executed at a price of $7.59 per share, amounting to a total value of $402,270. Following this sale, Hershberg retains ownership of 69,690 shares in the company. The sale comes amid significant market interest in ADPT, with the stock showing remarkable gains of over 112% in the past year and 77% over the last six months. According to InvestingPro data, analysts maintain a bullish outlook with a consensus target range of $7-12 per share. This transaction is part of routine filings disclosed to the Securities and Exchange Commission, providing transparency into insider trading activities. The company maintains strong liquidity with a current ratio of 2.89, indicating healthy short-term financial position. Discover more detailed insights and 10+ additional ProTips with InvestingPro’s comprehensive research reports.
In other recent news, Adaptive Biotechnologies Corporation reported fourth-quarter revenue of $47.5 million, surpassing analyst expectations of $46.15 million. The company also posted an adjusted loss per share of $0.23, which was narrower than the anticipated $0.25 loss. The Minimal Residual Disease (MRD) business, a significant contributor to the company’s revenue, grew by 31% year-over-year, reaching $40.1 million. However, the Immune Medicine segment saw a decline, with revenue falling 51% to $7.3 million.
Additionally, Adaptive Biotechnologies has provided revenue guidance for its MRD business in 2025, projecting between $175 million and $185 million. The company aims to keep operating expenses in the range of $340-$350 million and expects a cash burn of $60-$70 million for the year. Scotiabank (TSX:BNS) recently increased the price target for Adeptus Biotechnologies to $12, up from $10, while maintaining a Sector Outperform rating. This adjustment reflects Adeptus’s strong fiscal performance and strategic initiatives that are expected to drive future growth. The company ended 2024 with $256 million in cash and marketable securities, positioning it well for its projected financial targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.